Committee Composition

Jean-Jacques Bienaimé has served as a member of our board of directors since February 2004. Since May 2005, Mr. Bienaimé has served as Chief Executive Officer and director of BioMarin Pharmaceutical Inc., a publicly-held biopharmaceutical company. From November 2002 to April 2005, Mr. Bienaimé served as the Chairman, Chief Executive Officer and President of Genencor International, a biotechnology company acquired by Danisco A/S. From June 1998 to October 2002, Mr. Bienaimé was Chief Executive Officer and President of SangStat Medical, a biotechnology company. From October 1992 to May 1998, Mr. Bienaimé held various management positions, most recently as Senior Vice President of Corporate Marketing and Business Development, and Vice President and General Manager of the advanced therapeutic and oncology division of Rh™ne-Poulenc Rorer Pharmaceuticals (now The Sanofi-Aventis Group), a pharmaceutical company. Mr. Bienaimé received a B.S. in economics from the Ecole Supérieure de Commerce de Paris and an M.B.A. from the Wharton School at the University of Pennsylvania

Bradford S. Goodwin has served as a member of our board of directors and Audit Committee chairman since August 2009. Since 2006, Mr. Goodwin has served as president and CEO of Keren Pharmaceutical, a company focused on exploiting a novel, Nobel Prize winning method of gene silencing. Previously, Mr. Goodwin was CEO and a director of Novacea, Inc. from 2001 to 2006. He has held various executive positions, including 12-year tenure at Genentech, as well as nonexecutive chairman positions at Cotherix and PDL BioPharma. Mr. Goodwin is currently nonexecutive chairman of Facet Biotech Corp, and a director Rigel, Inc. He is a certified public accountant (CPA) and received a bachelor of science in administration from the University of California, Berkeley.

Robert T. Nelsen has served as a member of our board of directors since July 2000. Since July 1994, Mr. Nelsen has served as a senior principal of venture capital funds associated with ARCH Venture Partners, a venture capital firm. From April 1987 to July 1994, Mr. Nelsen served as Senior Manager of ARCH Development Partners LLC, a venture capital fund. Mr. Nelsen is also a director of Adolor Corporation, a publicly-held pharmaceutical company. Mr. Nelsen received a B.S. in biology and economics from the University of Puget Sound and an M.B.A. from the University of Chicago.